Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to Sell at StockNews.com

StockNews.com lowered shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research note released on Wednesday.

A number of other brokerages have also recently weighed in on ATNM. Maxim Group reduced their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating for the company in a research report on Tuesday, August 6th. B. Riley downgraded Actinium Pharmaceuticals from a buy rating to a neutral rating and reduced their target price for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating for the company in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $11.40.

Actinium Pharmaceuticals Stock Down 2.2 %

Shares of NYSE ATNM opened at $1.78 on Wednesday. The stock’s 50-day simple moving average is $3.85. The firm has a market cap of $53.01 million, a price-to-earnings ratio of -1.04 and a beta of 0.14. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, sell-side analysts forecast that Actinium Pharmaceuticals will post -1.38 earnings per share for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals in the 1st quarter valued at about $78,000. The Manufacturers Life Insurance Company purchased a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at approximately $92,000. Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Rhumbline Advisers raised its stake in shares of Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth $356,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.